HK1042238A1 - Treatment of symptoms of parkinson's disease with an agent comprising a dopaminergic substance and a local anaesthetic of the anilide group - Google Patents

Treatment of symptoms of parkinson's disease with an agent comprising a dopaminergic substance and a local anaesthetic of the anilide group

Info

Publication number
HK1042238A1
HK1042238A1 HK02103748A HK02103748A HK1042238A1 HK 1042238 A1 HK1042238 A1 HK 1042238A1 HK 02103748 A HK02103748 A HK 02103748A HK 02103748 A HK02103748 A HK 02103748A HK 1042238 A1 HK1042238 A1 HK 1042238A1
Authority
HK
Hong Kong
Prior art keywords
symptoms
disease
treatment
parkinson
agent
Prior art date
Application number
HK02103748A
Other languages
English (en)
Inventor
Lothar Saiger
Original Assignee
Lothar Saiger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lothar Saiger filed Critical Lothar Saiger
Publication of HK1042238A1 publication Critical patent/HK1042238A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
HK02103748A 1998-12-03 2002-05-17 Treatment of symptoms of parkinson's disease with an agent comprising a dopaminergic substance and a local anaesthetic of the anilide group HK1042238A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19855704A DE19855704C2 (de) 1998-12-03 1998-12-03 Verwendung einer Wirkstoffkombination zur Behandlung der Parkinsonschen Krankheit
PCT/DE1998/003612 WO2000032232A1 (de) 1998-12-03 1998-12-09 Mittel zur behandlung der symptome der parkinsonschen krankheit enthaltend ein zusätzliches lokalanästhetikum

Publications (1)

Publication Number Publication Date
HK1042238A1 true HK1042238A1 (en) 2002-08-09

Family

ID=7889787

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02103748A HK1042238A1 (en) 1998-12-03 2002-05-17 Treatment of symptoms of parkinson's disease with an agent comprising a dopaminergic substance and a local anaesthetic of the anilide group

Country Status (8)

Country Link
US (1) US6514999B1 (xx)
EP (1) EP1154794B1 (xx)
JP (1) JP2002531417A (xx)
AT (1) ATE238067T1 (xx)
DE (2) DE19855704C2 (xx)
ES (1) ES2200403T3 (xx)
HK (1) HK1042238A1 (xx)
WO (1) WO2000032232A1 (xx)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1414424A1 (de) * 2001-07-31 2004-05-06 Lothar Saiger Mittel zur behandlung der symptome von demenzerkrankungen enthaltend ein zusätzliches lokalanästhetikum
EP2178529A4 (en) * 2007-08-22 2011-09-14 Nathan D Zasler NEW APPLICATION OF TOPICAL NARCROGEN FOR MODULATION OF NEUROGENIC TREMOR
WO2014172372A1 (en) 2013-04-15 2014-10-23 Northwestern University Treatment for dopaminergic disorders
CA3102826A1 (en) * 2018-06-21 2019-12-26 Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno Disease modifying methods for treating neurodegenerative diseases using nootropic agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190763A (en) 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US6133299A (en) * 1993-02-25 2000-10-17 Warner-Lambert Company Methods for treating neurodegenerative diseases and disorders using N-(2,6-disubstituted aromatic)-N'-pyridinyl ureas and other anticonvulsant compounds
US5484608A (en) * 1994-03-28 1996-01-16 Pharmavene, Inc. Sustained-release drug delivery system
CA2195119C (en) * 1995-06-09 2001-09-11 Mark Chasin Formulations and methods for providing prolonged local anesthesia
DE19626621A1 (de) 1996-07-02 1998-01-08 Hexal Ag Pflaster zur transdermalen Anwendung von Pergolid
DE19716905C1 (de) 1997-04-22 1998-08-27 Iip Inst Fuer Ind Pharmazie Fo Stabile, wäßrige Lösung auf der Grundlage von Selegilin und Vorrichtung zu ihrer Verabreichung

Also Published As

Publication number Publication date
DE59808106D1 (de) 2003-05-28
JP2002531417A (ja) 2002-09-24
EP1154794B1 (de) 2003-04-23
EP1154794A1 (de) 2001-11-21
ATE238067T1 (de) 2003-05-15
DE19855704C2 (de) 2002-08-01
ES2200403T3 (es) 2004-03-01
US6514999B1 (en) 2003-02-04
DE19855704A1 (de) 2000-07-20
WO2000032232A1 (de) 2000-06-08

Similar Documents

Publication Publication Date Title
DE236684T1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
KR100190454B1 (ko) 모다피닐의 용도
Kim et al. Effect of acupuncture on behavioral hyperactivity and dopamine release in the nucleus accumbens in rats sensitized to morphine
Zhao et al. Acupuncture normalizes the release of accumbal dopamine during the withdrawal period and after the ethanol challenge in chronic ethanol-treated rats
DE69428523D1 (de) Verfahren zur behandlung von gemüts- oder geisteskrankheiten und von gemüts- oder geisteskrankheiten, die von anfällen begleitet sind
SE9401406D0 (sv) Pharmaceutical products for curing tumourous diseases and process for preparing same
IL225192A (en) Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury
ATE271874T1 (de) Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen
KR900015730A (ko) 정신장해 치료방해
MY132626A (en) CARBAZOLYL-SUBSTITUTED ETHANOLAMINES AS SELECTIVE ß-3 AGONISTS
KR920703043A (ko) 진해제로서의 gaba-b 선택적 효능제의 용도
DE69433818D1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
PT95760A (pt) Metodo para o tratamento de perturbacoes relacionadas com a ansiedade usando sertralina
BR0011823A (pt) Derivado de benzimidazol, composto, composição farmacêutica, uso de um derivado de benzimidazol, e, método para tratamento, prevenção ou alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo animal vivo
Vergoni et al. Neuroprotective effect of γ-hydroxybutyrate in transient global cerebral ischemia in the rat
DE14189577T9 (de) Behandlung von Blasenentzündung mit hochdosiertem Chondroitinsulfat
Sourkes " Rational hope" in the early treatment of Parkinson's disease
HK1042238A1 (en) Treatment of symptoms of parkinson's disease with an agent comprising a dopaminergic substance and a local anaesthetic of the anilide group
BR0211855A (pt) Medicamento e método para tratamento e melhoria da qualidade restauradora do sono
Timar et al. Behavioural changes in rats treated with a neurotoxic dose regimen of dextrorotatory amphetamine derivatives
DE69733169D1 (de) Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs
BR9914945A (pt) Processo para proporcionar terapiacosmética/medicinal
Gulyar et al. Innovative Light Therapy: 5. Anti-stress Effects of Polarized Polychromatic and Monochromatic Light from Halogen and LED Sources
CN104826005A (zh) 一种外用镇痛软膏及制配方法
ATE347364T1 (de) Quetiapin zur behandlung der dyskinesie in nicht- psychotischen patienten

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20071209